Dr. Graff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3303 S Bond Ave
Ste 7
Portland, OR 97239Phone+1 503-494-6594Fax+1 503-494-5385
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2006 - 2009- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2003 - 2006
George Washington University School of Medicine and Health SciencesClass of 2003
Certifications & Licensure
OR State Medical License 2006 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2012 Feb 06
- 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
- Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Start of enrollment: 2015 Oct 13
- Join now to see all
Publications & Presentations
PubMed
- Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.Matthew D Galsky, Karen A Autio, Christopher R Cabanski, Kristopher Wentzel, Julie N Graff
Clinical Cancer Research. 2025-02-18 - Daily life mobility detects frailty, falls, and functioning in older prostate cancer survivors treated with androgen deprivation therapy.Deanne C Tibbitts, Martina Mancini, Sydnee Stoyles, Nathan F Dieckmann, Julie N Graff
Journal of Geriatric Oncology. 2024-12-20 - Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer.Lisa N Chesner, Fanny Polesso, Julie N Graff, Jessica E Hawley, Alexis K Smith
Cancer Discovery. 2024-12-05
Lectures
- Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resis...ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- c15-148: Phase I/II trial of concurrent chemohormonal therapy using enzalutamide and cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Certain Toxic Effects Higher with Newer Prostate Cancer TherapiesMay 26th, 2023- Genetic Testing – the New Standard in Treatment for Advanced Prostate CancerJuly 6th, 2021
- Desert Storm Veteran in New Battle with Prostate CancerMarch 5th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
